Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stlage is a brand of Japanese Kampo (traditional herbal medicine) formulations developed and marketed by Alinamin Pharmaceutical (formerly Takeda Consumer Healthcare). Originally launched by Takeda Pharmaceutical in 2009, the Stlage product line is designed to treat various physical and gastrointestinal symptoms caused by stress and anxiety. The brand consists of several distinct formulations, including Stlage TYPE H (containing Hangekobokuto for throat discomfort and anxiety), Stlage TYPE I (containing Anchusan for stress-induced stomach pain and chronic gastritis), and Stlage TYPE G (containing Hangeshashinto for stress-induced diarrhea and soft stools). Other variants include Stlage TYPE SA (containing Seijobofuto for acne and dermatitis) and Stlage TYPE ZK (containing Chotosan for chronic headaches). These products are approved in Japan as Category 2 over-the-counter (OTC) medicines and are manufactured under contract by Tsumura.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Stlage.